Despite Early Success, Karyopharm’s Selinexor Faces Uncertain Path to Expansion

While achieving FDA approvals in rare cancers such as multiple myeloma and diffuse large B-cell lymphoma, Karyopharm’s cancer drug has a variety of scientific and market hurdles to clear.